Drug Search Results
More Filters [+]

Brexpiprazole

Alternative Names: brexpiprazole, opc-34712, opdc-34712, opdc34712, opdc 34712, rexulti, MTD-211, MTD211, MTD 211
Latest Update: 2024-07-31
Latest Update Note: News Article

Product Description

Brexpiprazole is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). It is also used with an antidepressant to treat depression when symptoms cannot be controlled by the antidepressant alone. Brexpiprazole is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain. (Sourced from: https://medlineplus.gov/druginfo/meds/a615046.html)

Mechanisms of Action: D2 Agonist,5-HT1A Agonist,5-HT2A Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Croatia | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Mexico | Netherlands | Norway | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United States | Vietnam

Approved Indications: Depressive Disorder | Depressive Disorder, Major | Schizophrenia

Known Adverse Events: Schizophrenia

Company: Otsuka
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Brexpiprazole

Countries in Clinic: China, Japan, Romania, United States

Active Clinical Trial Count: 31

Highest Development Phases

Phase 3: Alzheimer Disease|Autism Spectrum Disorder|Borderline Personality Disorder|Depressive Disorder, Major|Psychomotor Agitation|Schizophrenia|Stress Disorders, Post-Traumatic

Phase 1: Depressive Disorder

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2018-004899-35

P3

Active, not recruiting

Autism Spectrum Disorder

2025-10-19

2019-000723-40

P3

Active, not recruiting

Autism Spectrum Disorder

2025-07-19

NCT05326347

P3

Recruiting

Schizophrenia

2025-06-01

95%

331-102-00062

P3

Temporary halt

Schizophrenia

2025-05-31

Recent News Events